Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Interleukin 27 polymorphisms in HCV RNA positive patients: is there an impact on response to interferon therapy?

BMC infectious diseases - 1 Jan 2014

Zicca Emilia, Quirino Angela, Marascio Nadia, Nucara Stefania, Fabiani Fernanda, Trapasso Francesco, Perrotti Nicola, Strazzulla Alessio, Torti Carlo, Liberto Maria Carla, Focà Alfredo

Abstract excerpt

BACKGROUND: Interleukin 27 (IL-27) has pleiotropic properties that can either limit or enhance immune responses. Recent studies revealed that single nucleotide polymorphisms (SNPs) of the IL-27 promoter region modulate the development of infectious diseases and individual's susceptibility to therapeutic response. Little is known about the relationship between IL-27 single nucleotide polymorphisms and therapy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Base Sequence

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Ribavirin

Share to RNA, Viral

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 25236666
DOI: 10.1186/1471-2334-14-S5-S5
PMCID: PMC4160899

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Interleukin 27 polymorphisms in HCV RNA positive patients: is there an impact on response to interferon therapy?PMID 25236666Read ↗

Association of Interleukin-27 rs 153109 Single Nucleotide Polymorphism with Spontaneous Resolution of Hepatitis C Virus - Genotype 4a Infection in Egyptian Patients.Semantic proximity Read ↗

Impact of IL-27p28 (rs153109) and TNF-α (rs1800629) Genetic Polymorphisms on the Progression of HCV Infection in Egyptian Patients.Semantic proximity Read ↗

Impact of host IL28B rs12979860, rs8099917 in interferon responsiveness and advanced liver disease in chronic genotype 3 hepatitis C patients.Semantic proximity Read ↗

Polymorphisms and plasma levels of IL-27: impact on genetic susceptibility and clinical outcome of bladder cancer.Semantic proximity Read ↗

Interleukin 18 promoter variants (-137G>C and -607C>A) in patients with chronic hepatitis C: association with treatment response.Semantic proximity Read ↗

Tumour necrosis factor -308 and -238 promoter polymorphisms are predictors of a null virological response in the treatment of Brazilian hepatitis C patients.Semantic proximity Read ↗

IL-27-964 A/G polymorphism promoter polymorphism, serum IL-27, and vitamin D in multiple sclerosis: evidence from an egyptian case-control study.Semantic proximity Read ↗

Association between polymorphisms in IL27 gene and renal cell carcinoma.Semantic proximity Read ↗

Functional variant in the promoter region of IL-27 alters gene transcription and confers a risk for ulcerative colitis in northern Chinese Han.Semantic proximity Read ↗

Effect of Interleukin-27 Genetic Variants on Atrial Fibrillation Susceptibility.Semantic proximity Read ↗

Effect of interleukin-10 gene promoter polymorphisms -1082 G/A and -592 C/A on response to therapy in children and adolescents with chronic hepatitis C virus infection.Semantic proximity Read ↗

Gene polymorphisms of IL-10 and MxA in responders and non-responders to interferon therapy in HCV Egyptian patients genotype 4.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.